[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010.  CA Cancer J Clin. 2010;60(5):277-30020610543PubMedGoogle ScholarCrossref
2.
Sanda MG, Dunn RL, Michalski J,  et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors.  N Engl J Med. 2008;358(12):1250-126118354103PubMedGoogle ScholarCrossref
3.
Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment.  Urology. 2011;77(5):1035-104121420152PubMedGoogle ScholarCrossref
4.
Latini DM, Hart SL, Knight SJ,  et al; CaPSURE Investigators.  The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.  J Urol. 2007;178(3 pt 1):826-83117632144PubMedGoogle ScholarCrossref
5.
Tosoian JJ, Trock BJ, Landis P,  et al.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.  J Clin Oncol. 2011;29(16):2185-219021464416PubMedGoogle ScholarCrossref
6.
Lippman SM, Klein EA, Goodman PJ,  et al.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).  JAMA. 2009;301(1):39-5119066370PubMedGoogle ScholarCrossref
7.
Lippman SM, Goodman PJ, Klein EA,  et al.  Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).  J Natl Cancer Inst. 2005;97(2):94-10215657339PubMedGoogle ScholarCrossref
8.
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.  Stat Med. 1999;18(6):695-70610204198PubMedGoogle ScholarCrossref
9.
Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer.  J Clin Oncol. 2010;28(7):1117-112320124165PubMedGoogle ScholarCrossref
10.
Andriole GL, Bostwick DG, Brawley OW,  et al;  REDUCE Study Group.  Effect of dutasteride on the risk of prostate cancer.  N Engl J Med. 2010;362(13):1192-120220357281PubMedGoogle ScholarCrossref
11.
Thompson IM, Goodman PJ, Tangen CM,  et al.  The influence of finasteride on the development of prostate cancer.  N Engl J Med. 2003;349(3):215-22412824459PubMedGoogle ScholarCrossref
12.
Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.  N Engl J Med. 2011;365(2):97-9921675880PubMedGoogle ScholarCrossref
13.
Fleshner NE, Kapusta L, Donnelly B,  et al.  Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium.  J Clin Oncol. 2011;29(17):2386-239021537051PubMedGoogle ScholarCrossref
14.
Marshall JR, Tangen CM, Sakr WA,  et al.  Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-Grade Prostatic Intraepithelial Neoplasia: SWOG S9917 [published online September 6, 2011].  Cancer Prev Res (Phila Pa)21896650PubMedGoogle Scholar
15.
The Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.   N Engl J Med. 1994;330(15):1029-10358127329PubMedGoogle ScholarCrossref
16.
Gaziano JM, Glynn RJ, Christen WG,  et al.  Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial.  JAMA. 2009;301(1):52-6219066368PubMedGoogle ScholarCrossref
17.
Ford ES, Ajani UA, Mokdad AH. Brief communication: The prevalence of high intake of vitamin E from the use of supplements among US adults.  Ann Intern Med. 2005;143(2):116-12016027453PubMedGoogle ScholarCrossref
18.
Office of Dietary Supplements.  National Institutes of Health, Dietary Supplement Fact Sheet: Vitamin E. http://ods.od.nih.gov/factsheets/VitaminE-QuickFacts. Reviewed June 24, 2011. Accessed August 26, 2011
19.
Sano M, Ernesto C, Thomas RG,  et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease.  N Engl J Med. 1997;336(17):1216-12229110909PubMedGoogle ScholarCrossref
20.
Age-Related Eye Disease Study Research Group.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.  Arch Ophthalmol. 2001;119(10):1417-143611594942PubMedGoogle ScholarCrossref
21.
Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P.The Heart Outcomes Prevention Evaluation Study Investigators.  Vitamin E supplementation and cardiovascular events in high-risk patients.  N Engl J Med. 2000;342(3):154-16010639540PubMedGoogle ScholarCrossref
22.
Sesso HD, Buring JE, Christen WG,  et al.  Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.  JAMA. 2008;300(18):2123-213318997197PubMedGoogle ScholarCrossref
23.
Lee IM, Cook NR, Gaziano JM,  et al.  Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.  JAMA. 2005;294(1):56-6515998891PubMedGoogle ScholarCrossref
24.
Greenberg ER, Baron JA, Tosteson TD,  et al; Polyp Prevention Study Group.  A clinical trial of antioxidant vitamins to prevent colorectal adenoma.  N Engl J Med. 1994;331(3):141-1478008027PubMedGoogle ScholarCrossref
25.
Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial.  JAMA. 2002;288(6):715-72112169075PubMedGoogle ScholarCrossref
26.
McCance DR, Holmes VA, Maresh MJ,  et al; Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group.  Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial.  Lancet. 2010;376(9737):259-26620580423PubMedGoogle ScholarCrossref
27.
McNeil JJ, Robman L, Tikellis G, Sinclair MI, McCarty CA, Taylor HR. Vitamin E supplementation and cataract: randomized controlled trial.  Ophthalmology. 2004;111(1):75-8414711717PubMedGoogle ScholarCrossref
28.
Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ. Vitamin E supplementation and macular degeneration: randomised controlled trial.  BMJ. 2002;325(7354):1112098721PubMedGoogle ScholarCrossref
29.
Omenn GS, Goodman GE, Thornquist MD,  et al.  Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial.  J Natl Cancer Inst. 1996;88(21):1550-15598901853PubMedGoogle ScholarCrossref
30.
Cole BF, Baron JA, Sandler RS,  et al; Polyp Prevention Study Group.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.  JAMA. 2007;297(21):2351-235917551129PubMedGoogle ScholarCrossref
31.
Green S, Liu PY, O’Sullivan J. Factorial design considerations.  J Clin Oncol. 2002;20(16):3424-343012177102PubMedGoogle ScholarCrossref
Original Contribution
October 12, 2011

Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Author Affiliations

Author Affiliations: Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio (Dr Klein); Cancer Therapy and Research Center, University of Texas Health Science Center, San Antonio (Dr Thompson); SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington (Drs Tangen and Crowley and Mss Goodman and Darke); Department of Pathology, University of Colorado Health Science Center, Aurora (Dr Lucia); Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland (Drs Minasian, Ford, and Parnes); Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, and the Brigham and Women's Hospital, Division of Aging, Boston, Massachusetts (Dr Gaziano); Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center/University of Texas, Houston (Drs Karp and Lippman); Department of Urology, Mayo Clinic, Rochester, Minnesota (Dr Lieber); Department of Urology, Duke University Medical Center, Durham, North Carolina (Dr Walther); Department of Urology, Sunnybrook Medical Center, North York, Ontario, Canada (Dr Klotz); Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla (Dr Parsons); London Health Sciences Center, London, Surgical Oncology, Ontario, Canada (Dr Chin); Swedish Medical Center Cancer Institute, Medical Oncology, Seattle, Washington (Dr Goodman); University of California at Irvine, Department of Medicine, Orange (Dr Meyskens); and University of Michigan, Division of Hematology/Oncology, Ann Arbor (Dr Baker). Dr Karp's previous affiliation was Beth Israel Deaconess Medical Center, Medical Oncology, Boston, Massachusetts.

JAMA. 2011;306(14):1549-1556. doi:10.1001/jama.2011.1437
Abstract

Context The initial report of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found no reduction in risk of prostate cancer with either selenium or vitamin E supplements but a statistically nonsignificant increase in prostate cancer risk with vitamin E. Longer follow-up and more prostate cancer events provide further insight into the relationship of vitamin E and prostate cancer.

Objective To determine the long-term effect of vitamin E and selenium on risk of prostate cancer in relatively healthy men.

Design, Setting, and Participants A total of 35 533 men from 427 study sites in the United States, Canada, and Puerto Rico were randomized between August 22, 2001, and June 24, 2004. Eligibility criteria included a prostate-specific antigen (PSA) of 4.0 ng/mL or less, a digital rectal examination not suspicious for prostate cancer, and age 50 years or older for black men and 55 years or older for all others. The primary analysis included 34 887 men who were randomly assigned to 1 of 4 treatment groups: 8752 to receive selenium; 8737, vitamin E; 8702, both agents, and 8696, placebo. Analysis reflect the final data collected by the study sites on their participants through July 5, 2011.

Interventions Oral selenium (200 μg/d from L-selenomethionine) with matched vitamin E placebo, vitamin E (400 IU/d of all rac-α-tocopheryl acetate) with matched selenium placebo, both agents, or both matched placebos for a planned follow-up of a minimum of 7 and maximum of 12 years.

Main Outcome Measures Prostate cancer incidence.

Results This report includes 54 464 additional person-years of follow-up and 521 additional cases of prostate cancer since the primary report. Compared with the placebo (referent group) in which 529 men developed prostate cancer, 620 men in the vitamin E group developed prostate cancer (hazard ratio [HR], 1.17; 99% CI, 1.004-1.36, P = .008); as did 575 in the selenium group (HR, 1.09; 99% CI, 0.93-1.27; P = .18), and 555 in the selenium plus vitamin E group (HR, 1.05; 99% CI, 0.89-1.22, P = .46). Compared with placebo, the absolute increase in risk of prostate cancer per 1000 person-years was 1.6 for vitamin E, 0.8 for selenium, and 0.4 for the combination.

Conclusion Dietary supplementation with vitamin E significantly increased the risk of prostate cancer among healthy men.

Trial Registration Clinicaltrials.gov Identifier: NCT00006392

×